A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

Nature Medicine

Volumn 15, Issue 7, 2009, Pages 750-756

  Erkizan, Hayriye V ^a   Kong, Yali ^a   Merchant, Melinda ^b   Schlottmann, Silke ^a   Barber Rotenberg, Julie S ^a   Yuan, Linshan ^a   Abaan, Ogan D ^a   Chou, Tsu Hang ^b   Dakshanamurthy, Sivanesan ^a   Brown, Milton L ^a   Ren, Aykut ^a   Toretsky, Jeffrey A ^a,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA BINDING PROTEIN EWS; RNA HELICASE; RNA HELICASE A; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DEAD-BOX RNA HELICASES; HUMANS; MICE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; SARCOMA, EWING'S; SURFACE PLASMON RESONANCE; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650447477     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1983     Document Type: Article

References (40)

1. Mitelman, R., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245 (2007).
2. French, C.A. et al. Midline carcinoma of children and young adults with NUT rearrangement. J. Clin. Oncol. 22, 4135-4139 (2004).
3. Helman, LJ. & Meltzer, P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685-694 (2003).
4. Poppe, B. et al. Expression analyses identify MLL as a prominent target of Hq23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 103, 229-235 (2004).
5. Carroll, M. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947-4952 (1997).
6. Grier, H.E. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694-701 (2003).
7. Delattre, O. et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294-299 (1994).
8. Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. & Triche, T.J. Sequence-specific knockdown of EWS-FLl1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
9. Kovar, H., Ban, J. & Pospisilova, S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. 13, 275-281 (2003).
10. Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H. & Iwamoto, Y. EWS-Flil antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239-247 (1997).
11. Petermann, R. et al. Oncogenic EWS-Flil interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17, 603-610 (1998).
12. Nakatani, F. et al. Identification of p21WAFl/CIPl as a direct target of EWS-Flil oncogenic fusion protein. J. Biol. Chem. 278, 15105-15115 (2003).
13. Toretsky, J.A. et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 66, 5574-5581 (2006).
14. Lee, C.G. et al. RNA helicase A is essential for normal gastrulation. Proc. Natl. Acad. Sci. USA 95, 13709-13713 (1998).
15. Hartman, T.R. et al. RNA helicase A is necessary for translation of selected messenger RNAs. Nat. Struct. Mol. Biol. 13, 509-516 (2006).
16. Tetsuka, T. et al. RNA helicase A interacts with nuclear factor κB p65 and functions as a transcriptional coactivator. Eur. J. Biochem. 271, 3741-3751 (2004).
17. Valineva, T., Yang, J. & Silvennoinen, O. Characterization of RNA helicase A as component of STAT6-dependent enhanceosome. Nucleic Acids Res. 34, 3938-3946 (2006).
18. Myohanen, S. & Baylin, S.B. Sequence-specific DNA binding activity of RNA helicase A to the pl6INK4a promoter. J. Biol. Chem. 276, 1634-1642 (2001).
19. Zhong, X. & Safa, A.R. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells. J. Biol. Chem. 279, 17134-17141 (2004).
20. Nakajima, T. et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90, 1107-1112 (1997).
21. Anderson, S.F., Schlegel, B.P., Nakajima, T., Wolpin, E.S. & Parvin, J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19, 254-256 (1998).
22. Robb, G.B. & Rana, T.M. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol. Cell 26, 523-537 (2007).
23. Bhalla, J., Storchan, G.B., MacCarthy, C.M., Uversky, V.N. & Tcherkasskaya, O. Local flexibility in molecular function paradigm. Mol. Cell. Proteomics 5, 1212-1223 (2006).
24. Xie, H. et al. Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J. Proteome Res. 6, 1882-1898 (2007).
25. Ng, K.P. et al. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc. Natl. Acad. Sci. USA 104, 479-484 (2007).
26. Uren, A., Tcherkasskaya, O. & Toretsky, J.A. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry, 43, 13579-13589 (2004).
27. Terrone, D., Sang, S.L., Roudaia, L. & Silvius, J.R. Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 42, 13787-13799 (2003).
28. Voss, S.D., DeGrand, A.M., Romeo, G.R., Cantley, L.C. & Frangioni, J.V. An integrated vector system for cellular studies of phage display-derived peptides. Anal. Biochem. 308, 364-372 (2002).
29. Leeson, P.D. & Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881-890 (2007).
30. Gangwal, K. et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc. Natl. Acad. Sci. USA 105, 10149-10154 (2008).
31. Sanchez, G. et al. Alteration of cyclin Dl transcript elongation by a mutated transcription factor up-regulates the oncogenic Dlb splice isoform in cancer. Proc. Natl. Acad. Sci. USA 105, 6004-6009 (2008).
32. Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584 (1998).
33. Knoop, L.L. & Baker, S.J. EWS/FLI alters 5′-splice site selection. J. Biol. Chem. 276, 22317-22322 (2001).
34. Tirode, F. et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11, 421-429 (2007).
35. Delattre, O. et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165 (1992).
36. Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457-468 (2005).
37. Palermo, C.M., Bennett, C.A., Winters, A.C. & Hemenway, C.S. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leuk. Res. 32, 633-642 (2008).
38. Cheng, Y. et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24, 435-442 (2006).
39. Uren, A. et al. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 65, 6199-6206 (2005).
40. Frangioni, J.V. & Neel, B.G. Use of a general purpose mammalian expression vector for studying intracellular protein targeting: identification of critical residues in the nuclear lamin A/C nuclear localization signal. J. Cell Sci. 105, 481-488 (1993).